Semaglutide and Tirzepatide Each Cut Heart Failure Hospitalization and Death by Over 40% in Real-World HFpEF Patients

Five cohort studies using national US healthcare claims data (2018-2024). Two studies emulated the STEP-HFpEF DM (semaglutide) and SUMMIT (tirzepatide) randomized trials as benchmarks. Three studies used expanded eligibility criteria to evaluate real-world effectiveness, including a head-to-head comparison. Sitagliptin served as a placebo proxy. Propensity score weighting adjusted for comprehensive pretreatment characteristics. Follow-up was up to 52 weeks. Negative control outcomes, secondary endpoints, subgroups, and sensitivity analyses were prespecified.

HFpEF accounts for roughly half of all heart failure cases and has had few effective treatments until recently. While early randomized trials of semaglutide and tirzepatide showed promise, they were based on few clinical events. This study provides the first large-scale real-world evidence that these peptide drugs substantially reduce heart failure hospitalization and death — the outcomes that matter most to patients and clinicians. Published in JAMA, this is landmark evidence supporting GLP-1-based therapy for HFpEF.

This study is a pivotal piece of evidence in the expansion of GLP-1 receptor agonists beyond diabetes and obesity into cardiovascular medicine. Combined with the STEP-HFpEF and SUMMIT trial data, it builds a strong case for semaglutide and tirzepatide as standard treatments for cardiometabolic HFpEF. The finding that tirzepatide (a dual GIP/GLP-1 agonist) does not meaningfully outperform semaglutide (GLP-1 monoagonist) on hard outcomes suggests the GLP-1 pathway may be the primary driver of cardiac benefit.

This is an observational study using insurance claims data, not a randomized controlled trial, so residual confounding is possible despite propensity score adjustment. Sitagliptin was used as a placebo proxy, which may introduce bias if sitagliptin itself has cardiac effects. Claims data may not capture all clinical details, and drug adherence cannot be verified. The tirzepatide cohort is smaller due to its more recent market entry. Follow-up was limited to 52 weeks.